- Dana-Farber Cancer Institute is opening its newest satellite location for hematology and oncology services at St. Elizabeth's Medical Center in Brighton, Massachusetts.
- Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.
Tags: BasicResearch, LungCancer, Immunotherapy
- Scientists have redoubled efforts to disable the mutated cancer gene KRAS, which confers an especially poor prognosis and has proved extraordinarily difficult to target. New research has identified an additional hurdle: inhibiting KRAS can activate a backup pathway in cancer cells that enables them to survive and thrive in the oncogene's absence.
Tags: BasicResearch, Genomics
- Boston Mayor Martin Walsh reflected on his successful fight against childhood lymphoma at Dana-Farber’s annual celebration of survivorship. He was diagnosed at age 7 with Burkitt’s lymphoma, a rare, aggressive form of non-Hodgkin lymphoma that primarily affects children.
Tags: ChildhoodCancer, Survivorship
- Dana-Farber scientists report on a natural hormone that is increased by physical exercise and by exposure to cold improves blood sugar control, suppresses inflammation, and burns fat to mold leaner bodies in mice can be made in the laboratory and could have therapeutic potential for several diseases.
- Researchers find young adults who lack health care insurance are more likely to be diagnosed in advanced stages of cancer and have a higher risk of death.
Tags: Radiation, PopulationScience
- Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.
Tags: BreastCancer, ProstateCancer
- Dana-Farber researchers and colleagues report that men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting for the disease to become resistant to hormone-blockers.
- Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally.
Tags: OvarianCancer, TargetedTherapy
- A new study shows about half of non-small cell lung cancer (NSCLC) patients whose tumors no longer responded to conventional targeted drugs had their tumors shrink after receiving a new, more precisely targeted agent.
Tags: EGFR, LungCancer
Showing 31-40 of 536 items